Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Certara provides biosimulation software and regulatory science consulting services to pharmaceutical and biotech companies for drug development optimization. The company's platform combines proprietary software (D360, Phoenix, Simcyp) with expert services to model drug behavior, predict clinical outcomes, and accelerate regulatory submissions. Certara serves 2,000+ biopharma clients globally, with recurring software revenue (~65% of total) providing visibility while services revenue (~35%) ties to industry R&D spending cycles.
Certara monetizes through multi-year software subscriptions (typically 3-5 year contracts) with high renewal rates (90%+) and project-based consulting engagements. Pricing power derives from regulatory acceptance of biosimulation methodologies by FDA/EMA, switching costs due to embedded workflows in drug development pipelines, and network effects as more regulatory precedents validate the platform. The company benefits from biopharma outsourcing trends as clients seek specialized modeling expertise without building internal capabilities. Cross-selling opportunities exist as software clients purchase consulting services and vice versa.
Software annual recurring revenue (ARR) growth rate and net retention metrics - indicates stickiness and expansion within existing client base
New client wins among top 50 biopharma companies - validates competitive positioning and drives multi-year revenue visibility
Services backlog and utilization rates - leading indicator of near-term revenue conversion and biopharma R&D spending trends
Regulatory milestone adoptions - FDA/EMA guidance incorporating model-informed drug development expands addressable market
M&A activity - company has acquisition history (Pinnacle 21, Chemaxon) to expand capabilities and cross-sell opportunities
AI/ML disruption risk - emergence of generative AI and large language models could commoditize certain biosimulation capabilities or enable in-house development by large pharma, reducing reliance on third-party platforms
Regulatory acceptance variability - while FDA/EMA increasingly accept model-informed approaches, lack of standardized guidelines across therapeutic areas creates adoption uncertainty and limits market expansion
Biopharma R&D productivity pressures - industry-wide challenges in converting R&D spend to approved drugs could drive budget rationalization and consolidation of software vendors
Competition from larger enterprise software vendors (Dassault Systèmes' BIOVIA, Schrödinger) with broader life sciences platforms and deeper client relationships
In-house capability building by top 20 pharma companies investing in internal data science and modeling teams, potentially reducing outsourced services demand
Open-source modeling tools and academic software gaining regulatory acceptance could pressure pricing power in certain segments
Negative net margin (-3.1%) and near-breakeven operating margin (-0.4%) indicate profitability remains elusive despite scale, raising questions about path to sustainable earnings
Stock price decline (-53% over 1 year) creates employee retention risk through underwater equity compensation, potentially impacting services delivery quality
Acquisition integration risk - company has pursued inorganic growth strategy but must demonstrate ability to cross-sell and achieve synergies without disrupting core business
moderate - Revenue is tied to pharmaceutical R&D budgets which are relatively defensive but not immune to economic downturns. Large pharma clients (70%+ of revenue) maintain R&D spending through recessions to sustain pipelines, but biotech clients face funding pressures during risk-off environments. Software subscriptions provide stability through multi-year contracts, while services revenue is more cyclical and tied to discretionary project spending. Industry consolidation during downturns can temporarily disrupt client spending but creates long-term opportunities as merged entities rationalize systems.
Rising rates create headwinds through two channels: (1) Biotech funding environment deteriorates as venture capital and IPO markets contract, reducing services demand from smaller clients (~30% of revenue), and (2) Software valuation multiples compress as investors rotate from growth to value, pressuring stock price despite stable fundamentals. However, large pharma clients are less rate-sensitive. The company's debt load is modest (0.28 D/E) so direct financing cost impact is minimal. Current negative operating margin makes the business more sensitive to valuation multiple compression than earnings impact.
Moderate exposure through biotech client base. Tightening credit conditions reduce venture funding for early-stage biotech companies, which represent ~20-25% of Certara's client base. Services engagements from smaller biotechs are more vulnerable to cancellation or delay when funding becomes scarce. However, large pharma clients have strong balance sheets and maintain spending. Certara's own credit profile is solid with 2.09x current ratio and positive free cash flow, limiting direct credit risk.
growth - Investors are attracted to recurring software revenue model, 8.7% revenue growth, and exposure to secular trend of data-driven drug development. However, recent 53% stock decline and negative profitability have shifted sentiment from pure growth to 'show me' story requiring margin expansion proof. The 7.5% FCF yield at current depressed valuation attracts value-oriented investors betting on turnaround. Institutional ownership likely dominated by healthcare-focused growth funds and software specialists.
high - Stock has exhibited extreme volatility with -53% decline over past year and -40% over six months, indicating high beta to both healthcare IT sector and broader risk appetite. Small market cap ($1.1B) and negative profitability amplify volatility during market dislocations. Trading volumes likely thin, creating potential for sharp moves on earnings releases or biotech sector sentiment shifts. Volatility expected to remain elevated until company demonstrates consistent path to profitability.
